Elevation of serum FGF‐21 was found in patients with impairment of oxidative phosphorylation in muscle, and thus, FGF‐21 had been proposed as a biomarker for muscle‐manifesting mitochondrial diseases.13 This evidence concerns the gene FGF21 and inborn mitochondrial metabolism disorder.